OP004

OP004 is an investigational drug candidate developed by Opimend, a subsidiary of the Drug Rediscovery Group. It is designed to act as an opioid enhancer, increasing the analgesic potency of co-administered opioids. This mechanism is intended to allow for effective pain management at significantly lower opioid dosages, thereby reducing the risk of dose-dependent adverse effects such as respiratory depression, sedation, and the potential for opioid use disorder. As part of the Drug Rediscovery Group's portfolio, OP004 likely represents a repurposed or optimized pharmacological agent aimed at improving the safety profile of standard opioid therapies. Specific details regarding its molecular target and clinical development stage remain proprietary.